<DOC>
	<DOCNO>NCT00001063</DOCNO>
	<brief_summary>To compare effect stavudine ( d4T ) alone zidovudine ( AZT ) versus didanosine ( ddI ) alone AZT CD4 count , HIV RNA level , viral load HIV-infected patient [ AS PER AMENDMENT 3/21/97 : To compare effect d4T alone versus ddI alone versus AZT plus ddI ] . To compare safety d4T/AZT . AS PER AMENDMENT 3/21/97 : To evaluate pharmacokinetic interaction AZT d4T extracellular intracellular level . Although AZT ddI delay advancement HIV disease , benefit either drug proven temporary . d4T , new nucleoside analog favorable toxicity profile demonstrate activity HIV , offer additional therapeutic option . It reasonably assume benefit antiretroviral agent term delay clinical disease progression directly relate ability achieve sustain viral suppression ; thus , study measure effect viral load CD4 count .</brief_summary>
	<brief_title>The Effectiveness Three Drug Combinations HIV-Infected Patients Who Have Taken Zidovudine More Than 12 Weeks</brief_title>
	<detailed_description>Although AZT ddI delay advancement HIV disease , benefit either drug proven temporary . d4T , new nucleoside analog favorable toxicity profile demonstrate activity HIV , offer additional therapeutic option . It reasonably assume benefit antiretroviral agent term delay clinical disease progression directly relate ability achieve sustain viral suppression ; thus , study measure effect viral load CD4 count . Patients randomize blinded fashion receive AZT placebo combination open-label d4T ddI 48 week . AS PER AMENDMENT 3/21/97 : The study compose three arm : open-label d4T versus open-label ddI plus blinded AZT placebo versus blind AZT plus open-label ddI . Patients originally assign d4T + AZT arm , close 10/96 , give option discontinue AZT remain d4T monotherapy discontinue study drug . In addition , study participant ask participate pharmacology substudy .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Required patient whose CD4 count fall 200 cells/mm3 : PCP prophylaxis TMP/SMX , aerosolize pentamidine , dapsone . Allowed : Atovaquone , IV pentamidine , trimethoprimdapsone , clindamycinprimaquine , trimetrexate , TMP/SMX acute PCP . Topical antifungal , clotrimazole , ketoconazole , fluconazole , amphotericin B mucosal esophageal candidiasis . Itraconazole . Amphotericin B. Rifabutin . Isoniazid . Pyrazinamide . Clofazimine . Clarithromycin . Azithromycin . Ethambutol . Amikacin . Ciprofloxacin . Ofloxacin . Pyrimethamine . Sulfadiazine . Clindamycin . Ganciclovir . GCSF . Acyclovir ( 1000 mg/day ) . Erythropoietin . Antibiotics bacterial infection . Antipyretics . Analgesics . Antiemetics . Rifampin . Concurrent Treatment : Allowed : Local radiation therapy . Patients must : HIV infection . CD4 count 300600 cells/mm3 . More 12 week ( 24 week , AMENDED 3/31/96 ) total prior AZT ( &gt; 500 mg/day without serious adverse event ) . Subjects must actively take ZDV least 4 continuous week time study entry . No prior current history AIDS . No active opportunistic infection . Life expectancy least 2 year . Consent patient parent guardian le 18 year age . NOTE : Protocol approve prisoner enrollment . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Malignancy require systemic cytotoxic chemotherapy . Serious underlie medical condition HIV would reduce life expectancy &lt; 2 year . Concurrent Medication : Excluded : Antiretrovirals study drug . Foscarnet . Patients follow prior condition exclude : Unexplained temperature &gt; = 38.5 C 7 day chronic diarrhea ( &gt; = three stool daily ) 15 day , occur within 30 day prior study entry . History acute chronic pancreatitis . History grade 2 high peripheral neuropathy . History grade 3 bad intolerance 500600 mg/day AZT . Prior Medication : Excluded : ( within 30 day prior study entry ) Prior ddI , ddC , 3TC d4T ( 2 week total ) . Nonnucleoside reverse transcriptase inhibitor protease inhibitor . Biologic response modifier interferon IL2 . Other experimental therapy .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Didanosine</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Stavudine</keyword>
</DOC>